Daadaa N, Litaiem N, Karray M, et al. - Given that tranexamic acid (TXA) is an antifibrinolytic drug that has recently been used to treat erythematotelangiectatic rosacea (ETR), researchers conducted this retrospective study to assess the effectiveness and safety of intradermal microinjections of TXA for ETR. From January 2019 to February 2020, 6 patients, treated with TXA intradermal microinjections for ETR were included. Data reported that the mean number of monthly intradermal TXA microinjections was 5.1 ± 1.3. ETR can be treated safely and effectively with intradermal TXA microinjections. The optimal number of monthly sessions is still unknown.